Drug Discovery@nature.com 24 February 2012

TABLE OF CONTENTS 24 February 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Immunology presents a webcast series on Current Controversies Webcasts now available free on demand on the following topics: Lineage Differentiation HIV Vaccines Human Immunology Sponsored by:   News Top Wireless drug implant takes the trouble out of treatment doi:10.1038/nature.2012.10045 Microchip releases doses automatically, removing need for injections. Full Text Amyloid disease drug approved doi:10.1038/nbt0212-121b Pfizer's Vyndaqel (tafamidis) has been approved in Europe for the treatment of transthyretin amyloidosis, a rare and often fatal protein misfolding disorder. Full Text Enbrel patent surfaces doi:10.1038/nbt0212-123 Amgen has received another 17 years of patent protection on its blockbuster autoimmune drug Enbrel (etanercept). Full Text With bated breath, companies await approval for inhalable drugs doi:10.1038/nm0212-183 Drugmakers are increasingly looking to the lungs as a portal for quick and easy relief from a range of nonrespiratory conditions, with full decisions on approval awaited for Adasuve, an inhalable antipsychotic drug and Levadex, inhalable migraine medication. Full Text Analysis Top Strategies against Xalkori resistance doi:10.1038/scibx.2012.167 U.S. researchers have uncovered a plethora of mechanisms in ALK-rearranged lung cancers that could drive resistance to Pfizer's Xalkori crizotinib, suggesting that Xalkori, and possibly other ALK inhibitors, should be combined with drugs that target the EGFR and KIT pathways. Full Text Fresh from the Pipeline: Ruxolitinib doi:10.1038/nrd3652 In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with myelofibrosis. Full Text From the analyst's couch: The neuropathic pain market doi:10.1038/nrd3624 This article discusses the drug pipeline for neuropathic pain, for which the market is forecast to grow by 50% by 2020. Full Text Research Highlights Top Drug delivery: Encapsulation improves therapeutic stem cell action doi:10.1038/nrd3661 Therapeutic stem cells encapsulated in a biodegradable synthetic extracellular matrix show promise in mouse models of human glioblastoma surgical resection. Full Text Anticancer drugs: Keeping one step ahead doi:10.1038/nrd3664 A recent study proposes a new drug combination strategy to target drug-resistant chronic myeloid leukaemia. Full Text Psychiatric disorders: Why two is better than one doi:10.1038/nrn3181 The antidepressant fluoxetine increases synaptic plasticity in the amygdala and thereby facilitates fear erasure through extinction. Full Text Research & Reviews Top Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy doi:10.1038/nrd3628 This article outlines the challenges and opportunities for improving cognition in individuals suffering from psychiatric disorders, whose quality of life can be severely compromised by cognitive deficits. Full Text Targeting MET in cancer: rationale and progress doi:10.1038/nrc3205 Progress in understanding the structure and function of hepatocyte growth factor/scatter factor, MET and associated signalling components has led to the development of blocking antibodies and small-molecule MET kinase inhibitors, as discussed in this Review. Full Text Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates doi:10.1038/nbt.2108 Conjugating drugs to therapeutic antibodies is a promising strategy to increase their therapeutic efficacy. Shen et al. show that the local chemical environment of the conjugation site influences the in vivo stability and efficacy of the modified antibodies. Full Text Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure doi:10.1038/nbt.2089 Liver toxicity is one of the most common reasons for abandoning new drugs in development or withdrawing approved drugs from the market. Patel et al. show that drug-induced liver injury can be limited in mice by a small-molecule inhibitor of the gap-junctional protein connexin 32. Full Text Drug Discovery JOBS of the week Program / Associate Director � Vaccine, Center for Autoimmune and Inflammatory Diseases SRI International, Biosciences Division Post Doctoral Research Fellow University of Leicester Product Manager Drug Discovery Cellectis BioResearch Professorships & Lectureships University of Dundee Vaccine Research Scientist PULSE Scientific More Science jobs from Drug Discovery EVENT Imaging in Cancer Drug Development 14.-15.03.12 London, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.